| Vol. 12.09 – 12 March, 2021 |
| |
|
|
| By performing genome-wide ChIP-seq profiling in enzalutamide-resistant castration-resistant prostate cancer cells, scientists identified a set of androgen receptor (AR) binding sites with increased AR binding intensity. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors report the development of 3D culture analyses to separately quantify growth and invasion. They identified that alternate variants of IQSEC1, an ARF GTPase Exchange Factor, acted as switches to promote invasion over growth by controlling phosphoinositide metabolism. [Nature Communications] |
|
|
|
| Scientists identified ubiquitous βArrestin 1 as a regulator of androgen receptor function in castration-resistant prostate cancer. [Oncogene] |
|
|
|
| Investigators developed cationic solid lipid nanoparticles to carry siRNAs targeting EphA2 receptor tyrosine kinase (siEphA2), which is overexpressed in many solid tumors including prostate cancer. [Journal of Nanobiotechnology] |
|
|
|
| Researchers investigated nanostructured exfoliated black phosphorus in vitro effect on healthy and cancer prostate cell behavior. [Scientific Reports] |
|
|
|
| Scientists analyzed the molecular profile, as well as the functional consequences involved in the reciprocal interactions between prostate tumor cells and human astrocytes. [Molecular and Cellular Endocrinology] |
|
|
|
| Researchers investigated the effect of thalidomide on cellular functions of prostate stromal cells and human prostate smooth muscle contraction. [Prostate] |
|
|
|
| Investigators examined the cytotoxic effects of colchicine on PC3 cells to elucidate their possible underlying mechanisms. [Toxicology in Vitro] |
|
|
|
| DU145 and PC3 cells were cultured as 2D monolayers and 3D spheroids to compare sensitization of TRAIL-resistance cancer cells to TRAIL-mediated apoptosis via chemotherapy based on dimensionality. [PLoS One] |
|
|
|
|
| The authors present an overview of the current understanding of the intratumoral androgen biosynthesis in castration-resistant prostate cancer, with a special focus on the emerging roles of orphan nuclear receptors in this process. [Oncogene] |
|
|
|
|
| GT Biopharma, Inc. announced preclinical results for its ROR1 TriKEâ„¢ product candidate as a prospective therapy for the treatment of prostate cancer. [GT Biopharma, Inc.] |
|
|
|
| ORCA Therapeutics B.V. announced that upon review of all safety data from the fully enrolled, low- and mid-dose patient cohorts of the ongoing Phase I/IIa clinical study of ORCA-010 in treatment-naïve patients with localized prostate cancer, the independent Data and Safety Monitoring Board recommended the continuation of the study without modification. [ORCA Therapeutics B.V] |
|
|
|
|
| November 29 – December 1, 2021 Barcelona, Spain |
|
|
|
|
|
| Duke University – Durham, North Carolina, United States |
|
|
|
| Weill Cornell Medicine – New York, New York, United States |
|
|
|
| Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
| H. Lee Moffitt Cancer Center & Research Institute – Tampa, Florida, United States |
|
|
|
| Weill Cornell Medicine – New York, New York, United States |
|
|
|
|